Health Care [ 10/12 ] | Biotechnology [ 46/75 ]
NASDAQ | Common Stock
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs.
It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus.
The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; and VLA2112, a vaccine candidate to treat patients with epstein-barr virus.
It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally.
Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 19, 26 | -0.67 Decreased by -23.76% | -0.37 Decreased by -81.80% |
| Nov 20, 25 | -0.50 Decreased by -614.29% | -0.33 Decreased by -50.15% |
| Aug 12, 25 | -0.07 Increased by +79.41% | -0.39 Increased by +81.89% |
| May 7, 25 | -0.06 Decreased by -107.32% | -0.21 Increased by +71.10% |
| Mar 18, 25 | -0.54 Decreased by -17.93% | -0.17 Decreased by -228.79% |
| Nov 7, 24 | -0.07 Increased by +86.00% | -0.28 Increased by +75.00% |
| Aug 13, 24 | -0.34 Decreased by -41.67% | -0.27 Decreased by -25.93% |
| May 7, 24 | 0.82 Increased by +730.77% | 0.87 Decreased by -5.75% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 25 | 47.69 M Decreased by -9.92% | -50.02 M Decreased by -35.23% | Decreased by -104.89% Decreased by -50.13% |
| Sep 30, 25 | 29.41 M Decreased by -35.82% | -44.35 M Decreased by -380.24% | Decreased by -150.82% Decreased by -648.29% |
| Jun 30, 25 | 48.33 M Increased by +26.98% | -11.59 M Increased by +53.53% | Decreased by -23.97% Increased by +63.41% |
| Mar 31, 25 | 49.23 M Increased by +50.31% | -9.23 M Decreased by -115.67% | Decreased by -18.75% Decreased by -110.43% |
| Dec 31, 24 | 52.94 M Increased by +26.36% | -36.99 M Decreased by -15.02% | Decreased by -69.86% Increased by +8.97% |
| Sep 30, 24 | 45.82 M Increased by +20.36% | -9.24 M Increased by +73.01% | Decreased by -20.16% Increased by +77.58% |
| Jun 30, 24 | 38.06 M Decreased by -5.41% | -24.93 M Decreased by -47.37% | Decreased by -65.51% Decreased by -55.79% |
| Mar 31, 24 | 32.75 M Decreased by -2.25% | 58.91 M Increased by +424.98% | Increased by +179.86% Increased by +432.47% |